Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03663543 · ClinicalTrials.gov registry record · Phase 1
Intravenous Estrogen in Kidney Transplant Study
A Phase 1 study of Ischemia Reperfusion Injury, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03663543 is a Phase 1 study of Ischemia Reperfusion Injury that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03663543, a Phase 1 study of Ischemia Reperfusion Injury, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Ischemia perfusion injury (IRI) is a major cause of organ injury during kidney transplantation. Currently there are no treatments for IRI other than dialysis. Preliminary studies in female mice have found protection from IRI when given short term estrogen supplements. This study will look at the effect of intravenous estrogen given peri-operatively to reduce the effect of IRI in female kidney transplant recipients.
Conditions Studied
Interventions
- DRUG Normal saline
- DRUG Conjugated Estrogen
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-08-26 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03663543
The ClinicalTrials.gov registry entry for NCT03663543 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemia Reperfusion Injury appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT03663543 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03663543 about?
NCT03663543 is a clinical study titled "Intravenous Estrogen in Kidney Transplant Study". Ischemia perfusion injury (IRI) is a major cause of organ injury during kidney transplantation. Currently there are no treatments for IRI other than dialysis. Preliminary studies in female mice have found protection from IRI when given short term estrogen supplements. This study will look at the eff...
What is the current status of trial NCT03663543?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-08-26. Estimated completion is 2026-05-01.
What conditions does trial NCT03663543 study?
This clinical trial studies the following conditions: Ischemia Reperfusion Injury.
What interventions are being tested in trial NCT03663543?
The interventions under investigation include: Normal saline (DRUG), Conjugated Estrogen (DRUG).
Who is sponsoring clinical trial NCT03663543?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03663543 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemia Reperfusion Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.